Bristol: Late-Breaking Data for Breyanzi in Relapsed or Refractory Follicular,Mantle Cell Lymphomas

  Bristol Myers Squibb (NYSE: BMY) today announced the acceptance of two late-breaker abstracts for Breyanzi (lisocabtagene maraleucel) studies TRANSCEND FL and TRANSCEND NHL 001 for patients with relapsed or refractory follicular lymphoma (FL) and patients with relapsed or refractory mantle cell lymphoma (MCL), respectively, for presentation at the 2023 International Conference on Malignant Lymphoma (ICML). These results follow the topline announcement shared on May 1 of this year.

The two late-breaker studies include:

Abstract Title	Author	Session Title	Session Date/ Time (EDT)
TRANSCEND FL: Phase 2 study results of lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL)	Frank Morschhauser	Session 16 - Late Breaking Abstracts	Saturday, June 17, 2023 5:00 a.m. EDT (11:00 a.m. CEST)
Lisocabtagene maraleucel (liso-cel) in R/R MCL: primary analysis results from the MCL cohort of the single-arm, multicenter, seamless design TRANSCEND NHL 001 study	Michael Wang	Session 16 - Late Breaking Abstracts	Saturday, June 17, 2023 4:45 a.m. EDT (10:45 a.m. CEST)

All ICML accepted abstracts (except encore abstracts) will be available on June 9 on the ICML website.

https://www.biospace.com/article/releases/bristol-myers-squibb-to-present-late-breaking-data-for-breyanzi-lisocabtagene-maraleucel-in-relapsed-or-refractory-follicular-lymphoma-and-mantle-cell-lymphoma-at-2023-international-conference-on-malignant-lymphoma/